Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Epilepsy Res. 2016 Jul 27;126:185–196. doi: 10.1016/j.eplepsyres.2016.07.010

Fig. 9.

Fig. 9

Bumetanide decreases seizure susceptibility in glioma-implanted mice.

The latency to seizure onset (a) and the percent time exhibiting epileptiform activity (b) for two hours following kainic acid (10 mg/kg) administration in vehicle and bumetanide-treated mice implanted with a glioma two weeks prior compared to sham-implanted mice. n = 6 mice per experimental group. * Denotes a p value < 0.05 determined using a two-way ANOVA.